Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 5/2011

01-05-2011 | Clinical Research

Laparoscopic Sleeve Gastrectomy with Duodenojejunal Bypass for the Treatment of Type 2 Diabetes in Non-obese Patients: Technique and Preliminary Results

Authors: Salvador Antonio Navarrete, Jose Luis Leyba, Salvador Navarrete Llopis

Published in: Obesity Surgery | Issue 5/2011

Login to get access

Abstract

Background

Medical treatment of type 2 diabetes has often insufficient clinical results at long term. Although the surgical option is a well-established alternative for obese patients, the procedures in non-obese are currently being developed.

Methods

A 12-month prospective trial with ten diabetic non-obese patients who underwent laparoscopic sleeve gastrectomy with duodenojejunal bypass is presented. Changes in fasting blood glucose, HbA1c, weight, and BMI were determined.

Results

There was a significant reduction in fasting glycemia and HbA1c at 1 year postoperative (p < 0.004). One patient had an intra-abdominal bleeding and a wound infection treated with blood transfusion and antibiotic therapy, respectively. The BMI decreased 12.1% and in any case it was reduced to less than 20 kg/m2.

Conclusions

Laparoscopic sleeve gastrectomy with duodenojejunal bypass is a promising procedure for the treatment of non-obese patients with type 2 diabetes. Studies with large number of patients and longer follow-up are necessary to make definitive conclusions.
Literature
1.
Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–7.PubMedCrossRef
2.
Eliasson B, Eeg-Olofsson K, Cederholm J, et al. Antihyperglycemic treatment of type 2 diabetes: results from a national diabetes register. Diab Metab. 2007;33:269–76.CrossRef
3.
Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.PubMedCrossRef
4.
Pories WJ, Swanson MS, Kg McDonald, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339–50.PubMedCrossRef
5.
Shauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467–85.
6.
Greenway SE, Frank L, Greenway III, et al. Effects of obesity surgery on non-insulin-dependent diabetes mellitus. Arch Surg. 2002;137:1109–17.PubMedCrossRef
7.
Cohen RV, Schiavon CA, Pinheiro JS, et al. Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22–34 kg/m2: a report of 2 cases. Surg Obes Relat Dis. 2007;3:195–7.PubMedCrossRef
8.
9.
Ramos AC, Galvao MP, de Souza YM, et al. Laparoscopic duodenal-jejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI < 30 kg/m2 (LBMI). Obes Surg. 2009;19:307–12.PubMedCrossRef
10.
De Paula AL, Macedo AL, Rassi N, et al. Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. Surg Endosc. 2008;22:706–16.CrossRef
11.
Ferzli GS, Dominique E, Ciaglia M, et al. Clinical improvement after duodenojejunal bypass for nonobese type 2 diabetes despite minimal improvement in glycemic homeostasis. World J Surg. 2009;33:972–9.PubMedCrossRef
12.
Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes. A new perspective for and old disease. Ann Surg. 2004;239:1–13.PubMedCrossRef
13.
Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236–42.PubMedCrossRef
14.
Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741–9.PubMedCrossRef
15.
Langer FB, Reza MA, Bohdjalian A, et al. Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg. 2005;15:1024–9.PubMedCrossRef
16.
Vidal J, Ibarzabal A, Nicolau J, et al. Short-term effects on sleeve gastrectomy on type 2 diabetes mellitus in severely obese subjects. Obes Surg. 2007;17:1069–74.PubMedCrossRef
17.
De Paula AL, Macedo AL, Prudente AS, et al. Laparoscopic sleeve gastrectomy with ileal interposition (“neuroendocrine break”)—pilot study of a new operation. Surg Obes Relat Dis. 2006;2:464–7.PubMedCrossRef
18.
Moon Han S, Kim WW, Oh JH. Results of laparoscopic sleeve gastrectomy (LSG) at 1 year in morbidly obese Korean patients. Obes Surg. 2005;15:1469–75.PubMedCrossRef
19.
Cummings DE, Overduin J, Foster KE, et al. Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. Surg Obes Relat Dis. 2007;3:109–15.PubMedCrossRef
20.
Karamanakos SN, Vagenas K, Kalfarentzos F, et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy. A prospective, double blind study. Ann Surg. 2008;247:401–7.PubMedCrossRef
21.
Leyba JL, Aulestia SN, Llopis SN. Laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy for the treatment of morbid obesity. A prospective study of 117 patients. Obes Surg. 2011;21:212–6.PubMedCrossRef
22.
Leyba JL, Isaac J, Navarrete S, et al. Bypass gástrico por laparoscopia para la obesidad mórbida. Técnica y resultados en 150 pacientes con seguimiento de 3 a 48 meses. Revista de la Facultad de Medicina. 2007;30:73–9.
23.
Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250:234–41.PubMedCrossRef
24.
Li F, Zhang G, Liang J, et al. Sleeve gastrectomy provides a better control of diabetes by decreasing ghrelin in the diabetic Goto-Kakizaki rats. J Gastrointest Surg. 2009;13:2302–8.PubMedCrossRef
25.
Cohen RV (2007) Duodenojejunal bypass for the treatment of type II diabetes mellitus in patients with BMI 22-34. Presented at the center for the surgical treatment of morbid obesity and metabolic disorders, Hospital Sao Camilo and Baros Surgical Associates, Sao Paulo, Brazil.
26.
Gumbs A, Modlin IM, Ballantyne GH. Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss. Obess Surg. 2005;15:462–73.CrossRef
27.
le Roux CW, Aylwin S, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243:108–14.PubMedCrossRef
28.
Guidone C, Manco M, Valera-Mora E, et al. Mechanism of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes. 2006;55:2025–31.PubMedCrossRef
29.
Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and Insulin. J Clin Endocrinol Metab. 2005;90:359–65.PubMedCrossRef
30.
Korner J, Bessler M, Inabnet W, et al. Exaggerated GLP-1 and blunted GIP secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis. 2007;3:597–601.PubMedCrossRef
31.
Laferrère B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diab Care. 2007;30:1709–16.CrossRef
32.
Troy S, Soty M, Ribeiro L, et al. Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metab. 2008;8:201–11.PubMedCrossRef
Metadata
Title
Laparoscopic Sleeve Gastrectomy with Duodenojejunal Bypass for the Treatment of Type 2 Diabetes in Non-obese Patients: Technique and Preliminary Results
Authors
Salvador Antonio Navarrete
Jose Luis Leyba
Salvador Navarrete Llopis
Publication date
01-05-2011
Publisher
Springer-Verlag
Published in
Obesity Surgery / Issue 5/2011
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-011-0371-8

Other articles of this Issue 5/2011

Obesity Surgery 5/2011 Go to the issue

Economic Aspects

A Cost–Benefit Analysis of Bariatric Surgery on the South Plains Region of Texas

Clinical Report

Surgical Treatment of Morbid Obesity: Mid-term Outcomes of the Laparoscopic Ileal Interposition Associated to a Sleeve Gastrectomy in 120 Patients

Case Report

Reduced Phenytoin Levels in an Epileptic Patient following Roux-En-Y Gastric Bypass for Obesity

Clinical Research

Laparoscopic “Gastrojejunal Sleeve Reduction” as a Revision Procedure for Weight Loss Failure After Roux-En-Y Gastric Bypass

Clinical Research

Vitamin D Deficiency Before Bariatric Surgery: Should Supplement Intake Be Routinely Prescribed?

Clinical Research

Change in Predicted 10-Year Cardiovascular Risk Following Roux-en-Y Gastric Bypass Surgery: Who Benefits?